Treumer F, Wienand S, Purtskhvanidze K, Roider J, Hillenkamp J
Department of Ophthalmology, University Medical Center Schleswig-Holstein, Campus Kiel, Arnold Heller Str. 3, 24105, Kiel, Germany.
Department of Ophthalmology, University Medical Center Würzburg, Josef-Schneider Str. 11, 97080, Würzburg, Germany.
Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1115-1123. doi: 10.1007/s00417-017-3620-2. Epub 2017 Mar 9.
To assess the incidence of pigment epithelial detachment (PED) in age-related macular degeneration (AMD) with submacular hemorrhage (SMH) and its response to treatment with pars plana vitrectomy (ppV), subretinal co-application of recombinant tissue plasminogen activator (rtPA) and anti-VEGF, and an intravitreal gas tamponade.
Consecutive interventional case series of 132 eyes of 129 patients with neovascular AMD with SMH. All eyes underwent ppV with subretinal co-application of rtPA and bevacizumab followed by a gas tamponade. Postoperatively, two additional intravitreal anti-VEGF injections were applied monthly, followed by intravitreal anti-VEGF injections applied PRN thereafter. PEDs and SMHs were evaluated with SD-OCT pre- and postoperatively.
Preoperatively, 88 of 132 (67%) eyes were examined by OCT, and in 81 of these eyes the RPE could be visualised. A PED was found in 74 (91%) eyes, and no PED was found in five (6%) eyes. Median height of preoperative PED was 503 μm (range 150-1242, n = 65) and reduced to 344 (n = 62) and 306 μm (n = 27) after 3 and 12 months respectively. Two eyes showed a pre-existing rip of the RPE. Postoperatively, a rip was documented in 12 of 128 (9%) eyes. Median height of SMH was 762 μm (range 217-1840), median diameter was 4.3 (1.5-15) disc diameter. A complete displacement of the SMH from the fovea was achieved in 112 of 129 (87%) eyes. Overall, median best-corrected logMAR visual acuity (BCVA) improved significantly from preoperative 1.6 (0.5-2.0, n = 132) to 1.0 (0.2-2.0) 3 (n = 132) and 12 months (n = 74) postoperatively. Excluding eyes with pre-existing macular scars (n = 22), BCVA 3 months postoperatively was 0.8. Height of PED or SMH did not correlate with postoperatively BCVA, while size of SMH showed a mild correlation (rho = 0.25, p = 0.005).
PpV with subretinal co-application of rtPA and bevacizumab and an intravitreal gas tamponade effectively displaces SMH and improves BCVA. Preoperatively, PED is found in the majority of eyes. Height of PED or SMH did not correlate with postoperatively BCVA. Tears of the RPE occur as frequently as in exudative AMD without SMH.
评估年龄相关性黄斑变性(AMD)合并黄斑下出血(SMH)时色素上皮脱离(PED)的发生率,以及其对玻璃体视网膜手术(ppV)、视网膜下联合应用重组组织型纤溶酶原激活剂(rtPA)和抗血管内皮生长因子(anti-VEGF)及玻璃体腔内气体填塞治疗的反应。
对129例患有新生血管性AMD合并SMH的患者的132只眼进行连续干预性病例系列研究。所有患眼均接受ppV,视网膜下联合应用rtPA和贝伐单抗,随后进行气体填塞。术后每月额外进行两次玻璃体腔内抗VEGF注射,之后根据需要进行玻璃体腔内抗VEGF注射。术前和术后用频域光学相干断层扫描(SD-OCT)评估PED和SMH。
术前,132只眼中的88只(67%)接受了OCT检查,其中81只眼的视网膜色素上皮(RPE)可被观察到。74只(91%)眼中发现PED,5只(6%)眼中未发现PED。术前PED的中位高度为503μm(范围150 - 1242μm,n = 65),分别在3个月和12个月后降至344μm(n = 62)和306μm(n = 27)。2只眼存在RPE预先撕裂。术后,128只眼中的12只(9%)记录到撕裂。SMH的中位高度为762μm(范围217 - 1840μm),中位直径为4.3(1.5 - 15)视盘直径。129只眼中的112只(87%)实现了SMH从黄斑中心凹的完全移位。总体而言,最佳矫正视力(BCVA)的中位数从术前的1.6(0.5 - 2.0,n = 132)显著提高到术后3个月(n = 132)的1.0(0.2 - 2.0)和12个月(n = 74)的1.0。排除已有黄斑瘢痕的眼(n = 22),术后3个月的BCVA为0.8。PED或SMH的高度与术后BCVA无关,而SMH的大小显示出轻度相关性(rho = 0.25,p = 0.005)。
ppV联合视网膜下应用rtPA和贝伐单抗及玻璃体腔内气体填塞可有效移位SMH并改善BCVA。术前,大多数眼中可发现PED。PED或SMH的高度与术后BCVA无关。RPE撕裂的发生率与无SMH的渗出性AMD一样频繁。